Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis.

Abad C, Waschek JA.

Curr Pharm Des. 2011;17(10):1025-35. Review.

PMID:
21524252
2.

Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.

Gonzalez-Rey E, Varela N, Chorny A, Delgado M.

Curr Pharm Des. 2007;13(11):1113-39. Review.

PMID:
17430175
3.

Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP.

Abad C, Gomariz RP, Waschek JA.

Curr Top Med Chem. 2006;6(2):151-63. Review.

PMID:
16454764
4.

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.

Ganea D, Rodriguez R, Delgado M.

Cell Mol Biol (Noisy-le-grand). 2003 Mar;49(2):127-42. Review.

PMID:
12887096
5.

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis.

Baranowska-Bik A, Kochanowski J, Uchman D, Wolinska-Witort E, Kalisz M, Martynska L, Baranowska B, Bik W.

J Neuroimmunol. 2013 Oct 15;263(1-2):159-61. doi: 10.1016/j.jneuroim.2013.08.012. Epub 2013 Aug 30.

PMID:
24041830
8.

Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Tan YV, Waschek JA.

ASN Neuro. 2011 Oct 6;3(4). pii: e00065. doi: 10.1042/AN20110024. Review.

11.

VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.

Delgado M, Reduta A, Sharma V, Ganea D.

J Leukoc Biol. 2004 Jun;75(6):1122-30. Epub 2004 Mar 12.

12.
14.

Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells.

Kato H, Ito A, Kawanokuchi J, Jin S, Mizuno T, Ojika K, Ueda R, Suzumura A.

Mult Scler. 2004 Dec;10(6):651-9.

PMID:
15584490
15.

Vasoactive intestinal peptide as a healing mediator in Crohn's disease.

Arranz A, Abad C, Juarranz Y, Leceta J, Martinez C, Gomariz RP.

Neuroimmunomodulation. 2008;15(1):46-53. doi: 10.1159/000135623. Epub 2008 Jul 29. Review.

PMID:
18667799
17.

VIP-PACAP system in immunity: new insights for multitarget therapy.

Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C.

Ann N Y Acad Sci. 2006 Jul;1070:51-74. Review.

PMID:
16888149
18.
20.

Role of VIP and PACAP in islet function.

Winzell MS, Ahrén B.

Peptides. 2007 Sep;28(9):1805-13. Epub 2007 May 6. Review.

PMID:
17559974
Items per page

Supplemental Content

Write to the Help Desk